MAPT and Alzheimer disease: In the current report, in order to determine whether muscarinic antagonism has relevance as a psychotomimemtic agent in preclinical models of AD tauopathy, we investigate the effects of treatment in two tau models: the P301L/COMTKO [58] and the htau [59] model.